Trinity Biotech plc
17.00%
69,450,720
888721
896438504
Dec 1, 2025
Dec 4, 2025, 08:27 PM
Reporting Persons (3)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| MiCo IVD Holdings, LLC | Other | 17.00% | 69,450,720 | 0 | 69,450,720 |
| AI n M net Ltd. | Other | 17.00% | 69,450,720 | 0 | 69,450,720 |
| Wonyong Park | Individual | 17.00% | 69,450,720 | 69,450,720 | 0 |
Disclosure Items (6)
Class 'A' Ordinary Shares
Trinity Biotech plc
IDA Business Park, County Wicklow, L2, A98 H5C8
Item 2(a) of the Schedule 13D is hereby amended and restated in full as follows: This Amendment No. 5 is being filed jointly by MiCo IVD, AI n M net Ltd., a limited company incorporated in South Korea ("AI n M") and Wonyong Park (collectively, the "Reporting Persons"). Following completion of the 2025 MiCo IVD Purchase, AI n M beneficially owns all of the equity interests in MiCo IVD. Mr. Park serves as the manager, chief executive officer and president of MiCo IVD. Certain information regarding each director and executive officer of AI n M is set forth on Annex B filed herewith.
Item 2(b) of the Schedule 13D is hereby amended and restated in full as follows: The address of AI n M is 8F, 27 Hwangsaeul-ro 360beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea. The address of MiCo IVD is 85 Orchard Road, Skillman, New Jersey 08558. The address of Mr. Park is 15F Aju B/D, 679-5 Yeoksam-dong, Gangnam-gu, Seoul, Republic of Korea.
Item 2(c) of the Schedule 13D is hereby amended and restated in full as follows: The principal business of AI n M is wholesale and retail trade. The principal business of MiCo IVD is investing in securities of the Issuer. The principal occupation of Mr. Park is investment associate.
Item 2(e) of the Schedule 13D is hereby amended and restated in full as follows: During the last five years, none the Reporting Persons, nor any person identified in Item 2(a), has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 2(f) of the Schedule 13D is hereby amended and restated in full as follows: AI n M was formed in South Korea. MiCo IVD was formed in Delaware, United States. Mr. Park is a citizen of South Korea.
Item 3 of Schedule 13D is hereby amended to add the following: In connection with the 2025 MiCo IVD Purchase (as defined below), AI n M paid to DAYLI Holdings a total of 5,000,000,000 South Korean won from its working capital.
Item 5(a) of the Schedule 13D is hereby amended and restated in full as follows: The aggregate number and percentage of the Ordinary Shares beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on rows 7 through 11 and row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference. As of the date hereof, the Reporting Persons may be deemed to beneficially own 69,450,720 Ordinary Shares consisting of: (i) 2,237,969 ADSs, which represent 44,759,380 Ordinary Shares and (ii) 1,234,567 ADSs representing 24,691,340 Ordinary Shares issuable upon conversion of the Convertible Note. This represents an aggregate beneficial ownership of 17.0% of the Ordinary Shares, calculated on an as-converted basis assuming full conversion of the Convertible Note into ADSs. The percentage of beneficial ownership is based upon 383,881,600 Ordinary Shares reported to be outstanding by the Issuer as of March 15, 2025 in the Issuer's final prospectus filed pursuant to Rule 424(b)(3) on March 31, 2025 and the 24,691,340 Ordinary Shares represented by ADSs issuable upon conversion of the Convertible Note held by MiCo IVD. AI n M may be deemed to be the beneficial owner of the Ordinary Shares beneficially owned by MiCo IVD through its ownership interests in MiCo IVD. Mr. Park may be deemed to be the beneficial owner of the Ordinary Shares beneficially owned by MiCo IVD through his position as manager, chief executive officer and president of MiCo IVD. Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that AI n M or Mr. Park is the beneficial owner of Ordinary Shares referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and AI n M and Mr. Park expressly disclaim beneficial ownership of such shares, except to the extent of its or his pecuniary interest therein.
Item 5(b) of the Schedule 13D is hereby amended and restated in full as follows: The aggregate number and percentage of the Ordinary Shares beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on rows 7 through 11 and row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference.
Item 5(c) of the Schedule 13D is hereby amended and restated in full as follows: Except as set forth in this Schedule 13D, none of the Reporting Persons nor, to the best knowledge of the Reporting Persons, any other person named in Item 2, has engaged in any transaction in Ordinary Shares during the past 60 days.
Item 7 of Schedule 13D is hereby amended to add the following: Exhibit Annex B Exhibit No. 18 English Translation of Share Purchase Agreement, dated December 2, 2025, by and between DAYLI Holdings and AI n M. Exhibit No. 19 Joint Filing Agreement dated December 4, 2025, by and among the Reporting Persons. Except as expressly modified hereby, all provisions of the Schedule 13D shall continue in full force and effect.